Please login to the form below
Digital intelligence blog
Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools
Otsuka joins forces with IBM for Watson-based digital venture
Otsuka Digital Health will develop software to analyse psychiatric patient data
IBM's Watson-based cognitive computing product for oncology (PRNewsFoto/IBM)
Otsuka and IBM have formed a digital health company in Japan that will develop and market specialist software to analyse psychiatric patient data.
Known as Otsuka Digital Health, the partners' joint venture will formally established on Friday, with the pharma company taking an 85% stake in it to IBM Japan's 15%.
The company has been set up to market MENTAT, software whose development was based on Otsuka's knowledge of central nervous system disorders and IBM's Watson-based technology.
In a statement Otsuka said: “In psychiatry, patient symptoms and medical history are not usually enumerated and are entered into non-standardised electronic medical charts.
“Therefore it takes significant time and effort for hospital medical staff to analyse and understand a large volume of records, and a massive of amount data is not used well.”
The company hopes that its new digital health company and MENTAT software will enable hospital medical staff to use electronic medical records with more insight and, ultimate, provide better patient care.
The venture will operate independently of Otsuka's pharmaceutical business, where its CNS interests, where it is one of the five-biggest companies in the world, thanks to products such as Abilify.
COVID-19 Updates and Daily News
Featured jobs
-
Head of Health Psychology, London
-
Highly competitive salary
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
-
Senior Health Psychologist, London
-
Highly competitive salary
- Recognising HIV Vaccine Awareness Day
- Scientists discover new approach to treat brain tumours
- NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
- UICC launches global ATOM Coalition to increase access to essential cancer medicines
- Almirall and Evotec team up in multi-target dermatology alliance
- AstraZeneca’s COVID-19 vaccine receives EMA approval for use as third-dose booster
- NICE recommends Sanofi and Regeneron’s Libtayo for advanced CSCC
- Roche’s Polivy receives EC approval for lymphoma therapy
- Eli Lilly announces $2.1bn investment in new manufacturing sites
- How ‘Greenwashing’ accusations could delay the very changes its supporters demand
- A Medscape Oncology exclusive preview
- What does the future hold for clinical trial recruitment?
- Roche shares new positive Ocrevus data for MS patients
- Almirall and Evotec team up in multi-target dermatology alliance
- Evolve, evolve, evolve; a call to action to all leaders in the healthcare industry
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- First Herceptin biosimilar cleared in Europe
- India denies Vertex patent on cystic fibrosis drug Orkambi
PMHub
11 London
We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...
Latest intelligence
- How ‘Greenwashing’ accusations could delay the very changes its supporters demand
- Are shouts of companies ‘greenwashing’ to provide a façade of environmental and ethical respectability causing more harm than good? Or should we call out practices that we believe are papering...
- What does the future hold for clinical trial recruitment?
- The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
- When is an agency not an agency?
- The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
